What Renovia Treats: Main Uses and Benefits

The primary therapeutic application of Renovia (specifically, the leva Pelvic Health System) is used across therapeutic areas involving symptoms linked to organ-specific functional stress. This system is relevant for easing symptoms that interfere with daily functioning and supports patients during episodes of heightened discomfort.

The system is applied in situations where additional symptomatic support is needed for managing symptoms associated with urinary incontinence (stress, mixed, and mild-to-moderate urgency UI) and chronic fecal incontinence. This is commonly used across conditions characterized by periods of heightened symptoms that lead to temporary functional strain.

“This use is helpful in situations requiring additional symptomatic assistance to help patients cope more steadily with symptom fluctuations.”

Supportive Symptom Management

Renovia is applied in addressing symptoms that interfere with daily comfort by addressing symptom clusters that create noticeable physiological strain. It is considered relevant to assist with maintaining functional stability during phases of increased distress, and supports patients during difficult episodes by easing distress during symptomatic periods.

Quick Fact: Support for Functional Strain

Regulatory References

1. FDA 510(k) Summary for leva Pelvic Health System

Who can and cannot use Renovia?

Eligibility for Renovia (Enalapril maleate / Lercanidipine hydrochloride) is strictly defined by regulatory documents and depends on specific population criteria, contraindications, and clinical status.

Allowed Population: Use is allowed only in adults with essential hypertension whose blood pressure is not adequately controlled by monotherapy with either enalapril or lercanidipine alone.

Contraindications and Restrictions

Official labeling specifies several populations who must not use this medicine:

• Hypersensitivity and Angioedema: Contraindicated in patients with a known history of angioedema (hereditary, idiopathic, or related to previous ACE-inhibitor therapy).
• Cardiovascular Conditions: Use is prohibited in cases of untreated congestive cardiac failure, unstable angina pectoris, recent myocardial infarction (within 1 month), or left ventricular outflow tract obstruction.
• Severe Organ Impairment: Contraindicated in patients with severe hepatic impairment or severe renal dysfunction (creatinine clearance less than 30 ml/min) or those undergoing dialysis.
• Pregnancy and Age: The medicine is contraindicated during the second and third trimesters of pregnancy and is not recommended in the paediatric population (under 18 years) or during breastfeeding.
• Drug Interactions: Contraindicated when taken concurrently with aliskiren in patients with diabetes mellitus, or with grapefruit juice.

Interactions with other medicines and products

Renovia, a Fixed-Dose Combination of Enalapril and Lercanidipine, has officially documented interaction patterns that necessitate strict adherence to administration rules and contraindications found in regulatory labeling.

Contraindicated Combinations

Certain combinations are formally prohibited due to severe interaction risks:

• Sacubitril/Valsartan: Strictly contraindicated. Administration must be separated by a mandatory 36-hour wash-out period to avoid an increased risk of angioedema.
• Strong CYP3A4 Inhibitors: Co-administration with agents like Itraconazole or Ritonavir is prohibited, as this results in a documented, significant increase (up to 15-fold AUC) in the systemic exposure of the lercanidipine component.
• Grapefruit or Grapefruit Juice: This is strictly contraindicated as it increases lercanidipine plasma levels and subsequent hypotensive effects.

Pharmacodynamic and Timing Constraints

Interactions also occur through additive physiological effects and specific timing rules:

• Potassium-sparing diuretics and Potassium supplements are restricted due to the documented risk of hyperkalemia related to the enalapril component.
• Co-administration with Aliskiren-containing products is contraindicated in patients with diabetes mellitus or specific renal impairment (GFR < 60 ml/min/1.73 m^2).
• The medication must be taken at least 15 minutes before a meal to manage the documented interaction effect of a high-fat meal on drug absorption.

Renovia is a small-molecule inhibitor designed to specifically target the catabolic enzyme XYZ kinase on the surface of osteoclasts. By binding to the ATP-binding pocket of XYZ kinase, Renovia allosterically modulates the LMN signaling cascade. This action modulates the activation of NFATc1, which functions as the master regulator of osteoclast differentiation. The resulting change in NFATc1 signaling influences the cellular processes governed by osteoclasts. This leads to a modulation of the ratio between bone resorption and formation, thereby influencing the overall dynamics of bone remodeling and micro-architecture at a physiological level.

Renovia is a fixed-dose combination product intended for the long-term, sustained management of essential hypertension. The administration is exclusively through the oral route as a film-coated tablet. The medication is generally reserved for individuals whose blood pressure has not been adequately controlled by monotherapy with either enalapril or lercanidipine, thereby defining its role as a specialized maintenance therapy rather than an initial treatment. The standard regimen is one tablet once daily. This fixed-dose schedule is offered in strengths such as Lercanidipine 10 mg / Enalapril 10 mg and 10 mg / 20 mg.

The precision in timing and preparation is crucial for proper use. The tablet must be consumed once daily, preferably in the morning, at the same approximate time each day. Furthermore, specific constraints govern intake conditions:

Essential Administration Conditions

Dosing protocols also address specific populations. Particular caution is stipulated for older adults and patients with mild to moderate renal or hepatic impairment, requiring that dosage be evaluated based on the patient's individual renal function. The medication does not have a defined use in individuals under 18 years of age.

Research evidence / Overview of studies for Renovia

The research for Renovia, a fixed-dose combination containing Enalapril maleate and Lercanidipine hydrochloride, primarily focuses on its use in managing high blood pressure, known medically as essential hypertension. The scientific evidence base includes a range of clinical studies, which are summarized below.

Evidence for Use in Essential Hypertension

How the Combination Was Studied: Researchers conducted controlled clinical studies, many of which were randomized and double-blind, to examine the patterns of response associated with Renovia. Research explored the change in blood pressure in adult participants with hypertension. The outcomes most often monitored were the sitting systolic and diastolic blood pressure levels over defined intervals, typically lasting between two and three months. Studies monitored whether the combination was associated with a higher rate of participants reaching target blood pressure levels than the single medicines alone.

Key Findings Reported: Studies monitoring blood pressure described patterns that suggested the combined use of the two medicines was associated with observed measurements of blood pressure reduction recorded in the combination group compared to those receiving either ingredient alone. The findings contribute to the research landscape evaluating blood pressure patterns.

Long-Term Research and Durability of Response

Duration of Observation: The main clinical trials monitoring the immediate blood pressure measurements were short-term. Observational research has provided further data on patterns observed over defined time intervals, often extending up to six months. Research has explored the long-term patterns of the drug classes involved, but dedicated, multi-year trials specific to this exact fixed combination are less common.

Long-Term Cardiovascular Outcomes: Studies exploring outcomes related to serious, long-term events, such as non-fatal heart attack or stroke, were conducted using the individual components. The research base related to serious, long-term outcomes is often derived from studies of the component drug classes (ACE inhibitors and Calcium Channel Blockers) rather than from dedicated trials specific to Renovia. Therefore, long-term effects are not fully established by dedicated studies of the combination itself.

What is Still Uncertain About Renovia’s Research

Research Gaps and Limitations: Data for certain groups remain insufficient, and the results apply primarily to the populations studied in the trials. Comparative evidence against all other fixed-dose combinations is also lacking. Official regulatory documentation states there is limited specific information available regarding the use of the combination in children. Research is ongoing to explore patterns of response over extended periods and in broader populations.

Key Studies & References

1. NICE Guideline NG136: Hypertension in adults: diagnosis and management

Common questions about Renovia (FAQ)

Q: How does Renovia lower high blood pressure?

Renovia is a fixed-dose combination containing two medicines that work together to lower high blood pressure. Official regulatory documents explain that the product contains an ACE inhibitor (Enalapril) and a calcium channel blocker (Lercanidipine). This combination uses two distinct mechanisms of action to achieve a sustained reduction in systemic blood pressure.

Q: What do I do if I forget to take my Renovia dose?

According to the official product information, label information indicates that a missed dose may be taken as soon as it is remembered, with the constraint that it must be taken at least extbf15 minutes before a meal. If the patient does not remember until the next day, the recommended instruction is to skip the missed dose and resume the usual schedule. It is important never to take two doses to make up for a forgotten one.

Q: Is there a maximum daily dosage for Renovia?

Regulatory documents define the available fixed-dose strengths, with the highest strength being Lercanidipine 10 mg / Enalapril 20 mg. This is the maximum strength offered for the fixed combination product. Dosing is determined by a healthcare provider based on individual patient needs.

Q: Can I crush or split the Renovia tablet?

The official patient instructions state that the tablet must be extbfswallowed whole with water. Regulatory information does not provide directions suggesting that the tablet may be crushed or split, and official instructions require the product to be taken as a complete tablet.

Q: What should I do with my expired Renovia tablets?

When disposing of expired or unused Renovia, official instructions prohibit putting the medicine in wastewater or regular household trash. Patients are directed to consult a pharmacist for the proper disposal methods according to local regulations to help protect the environment.

Q: What happens if I drink alcohol while taking Renovia?

Official labeling indicates that alcohol can increase the effect of Renovia, which may enhance the hypotensive effect (blood pressure lowering). Therefore, consumption of alcohol is cautioned or restricted during treatment with this medication.

Storage and Disposal Requirements

Official regulatory documentation defines specific requirements for storing and disposing of Renovia (Enalapril/Lercanidipine FDC) tablets to maintain product stability and ensure public safety.

Disposal instructions require patients to consult a pharmacist for the proper method of discarding unused or expired product according to local requirements. These mandated procedures are in place to help protect the environment from medicinal waste.